Skip to Content

Rimegepant Dosage

Medically reviewed by Drugs.com. Last updated on March 31, 2020.

Applies to the following strengths: 75 mg

Usual Adult Dose for Migraine

75 mg orally
Maximum dose: 75 mg in a 24-hour period

Comments:
-This drug is not for the preventive treatment of migraine.
-The safety of treating more than 15 migraines in a 30-day period is unknown.

Use: For the acute treatment of migraine with or without aura.

Renal Dose Adjustments

Mild to Severe Renal Impairment (CrCl 15 mL/min or greater): No adjustment recommended
ESRD (CrCl less than 15 mL/min): Avoid use

Liver Dose Adjustments

Mild to Moderate Hepatic Impairment (Child-Pugh A or B): No adjustment recommended
Severe Hepatic Impairment (Child-Pugh C): Avoid use

Dose Adjustments

Concomitant Use with CYP450 3A4 Inhibitors:
-Strong CYP450 3A4 inhibitors: Avoid concomitant administration
-Moderate CYP450 3A4 inhibitors: Avoid a second dose of rimegepant within 48 hours

Concomitant Use with CYP450 3A4 Inducers:
-Strong or moderate CYP450 3A4 inducers: Avoid concomitant administration as this may lead to loss of efficacy of rimegepant

Concomitant Use with P-gp or BCRP:
-Avoid concomitant administration with P-gp or BCRP inhibitors

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to active substance or any product excipients; delayed serious hypersensitivity has occurred

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Place on tongue (or under tongue) and allow to disintegrate in saliva and swallow; additional liquid is not necessary
-Do not take more than 1 dose in 24-hours

Preparation techniques:
-Use dry hands when opening the blister pack
-Peel back the foil and gently remove the tablet; do not push tablet through foil
-Place tablet on tongue or under tongue as soon as the blister is opened

Storage:
-Do not store table outside the blister pack

Patient advice:
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
-Patients should be instructed to contact their healthcare provider if they experience signs or symptoms of an allergic reaction.
-Patients should be advised to speak with their healthcare provider if they become pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed during therapy.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about rimegepant

Consumer resources

Other brands: Nurtec ODT

Professional resources

Related treatment guides